Idexx Laboratories (IX1) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IX1 Analyst Ratings

Moderate Buy

4 Buy

3 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Idexx

Laboratories

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IX1 Stock 12 Month Forecast

Average Price Target

€613.81

▲(27.90% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Idexx Laboratories in the last 3 months. The average price target is €613.81 with a high forecast of €706.72 and a low forecast of €583.81. The average price target represents a 27.90% change from the last price of €479.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"457":"€457","582":"€582","707":"€707","519.5":"€519.5","644.5":"€644.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":706.71812155,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€706.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":613.8059047416667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€613.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":583.81062215,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€583.81</span>\n  </div></div>","useHTML":true}}],"tickPositions":[457,519.5,582,644.5,707],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,477.4,495.0398555038461,512.6797110076923,530.3195665115385,547.9594220153846,565.5992775192308,583.2391330230769,600.8789885269231,618.5188440307692,636.1586995346154,653.7985550384615,671.4384105423077,689.0782660461539,{"y":706.71812155,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,477.4,487.8927619032051,498.3855238064102,508.8782857096154,519.3710476128205,529.8638095160256,540.3565714192308,550.8493333224359,561.3420952256411,571.8348571288461,582.3276190320513,592.8203809352565,603.3131428384615,{"y":613.8059047416667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,477.4,485.5854324730769,493.77086494615384,501.95629741923074,510.1417298923077,518.3271623653845,526.5125948384615,534.6980273115385,542.8834597846153,551.0688922576923,559.2543247307692,567.439757203846,575.625189676923,{"y":583.81062215,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":549.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":517,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":553.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":636,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":568.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":566.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":552.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":486.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":469.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":486.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":458.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":485.9,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":477.4,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€706.72

Average Price Target€613.81

Lowest Price Target€583.81

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrea Alfonso

UBS

€588.2

Hold

22.57%

Upside

Assigned

09/16/26

Analysts Conflicted on These NA Names: Rapport Therapeutics, Inc. (NASDAQ: RAPP), Idexx Laboratories (NASDAQ: IDXX) and Waystar Holding Corp. (NASDAQ: WAY)

Michael Ryskin

Bank of America Securities

€579.42→€583.81

Hold

21.65%

Upside

Reiterated

08/14/26

Idexx: Neutral Stance Maintained as Long-Term Outlook Stays Opaque, Target Price Raised to $665

Jonathan Block

Stifel Nicolaus

€592.59

Buy

23.48%

Upside

Reiterated

08/14/26

Analysts Are Bullish on Top Healthcare Stocks: Idexx Laboratories (IDXX), Nkarta (NKTX)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

08/13/26

Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (NASDAQ: ACHV) and Idexx Laboratories (NASDAQ: IDXX)

Glen Santangelo

Barclays

€623.32

Buy

29.88%

Upside

Reiterated

08/11/26

Idexx Laboratories (IDXX) Receives a Buy from Barclays

Erin Wright

Morgan Stanley

€706.72

Buy

47.26%

Upside

Reiterated

08/05/26

Idexx Laboratories (IDXX) Receives a Buy from Morgan Stanley

Daniel Grosslight

Citi

€570.64→€588.2

Hold

22.57%

Upside

Reiterated

08/05/26

Citi Keeps Their Hold Rating on Idexx Laboratories (IDXX)

Keith Devas

Jefferies

€695.31

Buy

44.89%

Upside

Reiterated

05/06/26

Idexx Laboratories (IDXX) Receives a Buy from Jefferies

David Westenberg

Piper Sandler

€680.38→€658.43

Hold

37.20%

Upside

Reiterated

02/09/26

Idexx Laboratories price target lowered to $750 from $775 at Piper SandlerIdexx Laboratories price target lowered to $750 from $775 at Piper Sandler

Mark Massaro

BTIG

€728.67→€702.33

Buy

46.35%

Upside

Reiterated

02/03/26

Idexx Laboratories price target lowered to $800 from $830 at BTIGIdexx Laboratories price target lowered to $800 from $830 at BTIG

Chris Schott

J.P. Morgan

€680.38

Buy

41.78%

Upside

Reiterated

11/03/25

J.P. Morgan Keeps Their Buy Rating on Idexx Laboratories (IDXX)

Daniel Clark

Leerink Partners

€654.04→€689.16

Buy

43.60%

Upside

Reiterated

11/03/25

Idexx Laboratories price target raised to $785 from $745 at LeerinkIdexx Laboratories price target raised to $785 from $745 at Leerink

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrea Alfonso

UBS

€588.2

Hold

22.57%

Upside

Assigned

09/16/26

Analysts Conflicted on These NA Names: Rapport Therapeutics, Inc. (NASDAQ: RAPP), Idexx Laboratories (NASDAQ: IDXX) and Waystar Holding Corp. (NASDAQ: WAY)

Michael Ryskin

Bank of America Securities

€579.42→€583.81

Hold

21.65%

Upside

Reiterated

08/14/26

Idexx: Neutral Stance Maintained as Long-Term Outlook Stays Opaque, Target Price Raised to $665

Jonathan Block

Stifel Nicolaus

€592.59

Buy

23.48%

Upside

Reiterated

08/14/26

Analysts Are Bullish on Top Healthcare Stocks: Idexx Laboratories (IDXX), Nkarta (NKTX)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

08/13/26

Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (NASDAQ: ACHV) and Idexx Laboratories (NASDAQ: IDXX)

Glen Santangelo

Barclays

€623.32

Buy

29.88%

Upside

Reiterated

08/11/26

Idexx Laboratories (IDXX) Receives a Buy from Barclays

Erin Wright

Morgan Stanley

€706.72

Buy

47.26%

Upside

Reiterated

08/05/26

Idexx Laboratories (IDXX) Receives a Buy from Morgan Stanley

Daniel Grosslight

Citi

€570.64→€588.2

Hold

22.57%

Upside

Reiterated

08/05/26

Citi Keeps Their Hold Rating on Idexx Laboratories (IDXX)

Keith Devas

Jefferies

€695.31

Buy

44.89%

Upside

Reiterated

05/06/26

Idexx Laboratories (IDXX) Receives a Buy from Jefferies

David Westenberg

Piper Sandler

€680.38→€658.43

Hold

37.20%

Upside

Reiterated

02/09/26

Idexx Laboratories price target lowered to $750 from $775 at Piper SandlerIdexx Laboratories price target lowered to $750 from $775 at Piper Sandler

Mark Massaro

BTIG

€728.67→€702.33

Buy

46.35%

Upside

Reiterated

02/03/26

Idexx Laboratories price target lowered to $800 from $830 at BTIGIdexx Laboratories price target lowered to $800 from $830 at BTIG

Chris Schott

J.P. Morgan

€680.38

Buy

41.78%

Upside

Reiterated

11/03/25

J.P. Morgan Keeps Their Buy Rating on Idexx Laboratories (IDXX)

Daniel Clark

Leerink Partners

€654.04→€689.16

Buy

43.60%

Upside

Reiterated

11/03/25

Idexx Laboratories price target raised to $785 from $745 at LeerinkIdexx Laboratories price target raised to $785 from $745 at Leerink

Stocks with the Highest Top Analyst Consensus in the General Sector

STDNStandard Nuclear

SKHYSK Hynix

ITGITG Inc. Class A

LIMENeutron Holdings, Inc.

EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Idexx Laboratories

3 Months

Daniel ClarkLeerink Partners

Success Rate

7/9 ratings generated profit

Average Return

+7.60%

Copying Daniel Clark's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +7.60% per trade.

1 Year

Mark MassaroBTIG

Success Rate

7/10 ratings generated profit

Average Return

+21.72%

Copying Mark Massaro's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +21.72% per trade.

2 Years

Mark MassaroBTIG

Success Rate

7/10 ratings generated profit

Average Return

+6.26%

Copying Mark Massaro's trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +6.26% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IX1 Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IX1 has received 7 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. IX1 average Analyst price target in the past 3 months is 613.81.

Each month's total comprises the sum of three months' worth of ratings.

IX1 Financial Forecast

IX1 Earnings Forecast

Next quarter’s earnings estimate for IX1 is €3.22 with a range of €3.15 to €3.26. The previous quarter’s EPS was €3.70. IX1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year IX1 has Performed in-line its overall industry.

IX1 Sales Forecast

Next quarter’s sales forecast for IX1 is €1.03B with a range of €1.02B to €1.04B. The previous quarter’s sales results were €1.05B. IX1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year IX1 has Performed in-line its overall industry.

IX1 Stock Forecast FAQ

What is DE:IX1’s average 12-month price target, according to analysts?

Based on analyst ratings, Idexx Laboratories’s 12-month average price target is 613.81.

What is DE:IX1’s upside potential, based on the analysts’ average price target?

Idexx Laboratories has 27.90% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Idexx Laboratories a Buy, Sell or Hold?

Idexx Laboratories has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 3 hold ratings and 0 sell ratings.

What is Idexx Laboratories’s share price target?

The average share price target for Idexx Laboratories is 613.81. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €706.72 ,and the lowest forecast is €583.81. The average share price target represents 27.90% Increase from the current price of €479.9.

What do analysts say about Idexx Laboratories?

Idexx Laboratories’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Idexx Laboratories?

To buy shares of DE:IX1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Idexx Laboratories (IX1) Stock Forecast & Price Target

IX1 Analyst Ratings

IX1 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Idexx Laboratories

IX1 Analyst Recommendation Trends

IX1 Financial Forecast

IX1 Earnings Forecast

IX1 Sales Forecast

IX1 Stock Forecast FAQ

Detailed List of Analyst Forecasts